Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals

Dow Jones

Dec 03, 2024

By Denny Jacob

Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.

Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.

The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.

Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.

Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.

The proposed transaction is expected to close by the end of the first quarter of 2025.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 03, 2024 07:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488911662"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488911662\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488911662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488911662","market":"hk","top_or_hot":-1,"title":"Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-03 20:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488911662","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488911662","pubTimestamp":1733229600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.The proposed transaction is expected to close by the end of the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4139":"生物科技","CHRS":"Coherus Biosciences"},"translate_title":"Coherus BioSciences股价因与Intas Pharmaceuticals达成剥离协议而上涨22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n\n\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n\n\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n\n\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n\n\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n\n\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 07:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}